Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Can we afford to let sleeping dogs lie?

Blood - 1 Mar 2005

Deininger Michael W N, Holyoake Tessa L

Abstract excerpt

In patients with chronic myelogenous leukemia (CML) mutations of the BCR-ABL kinase domain (KD) have been identified as the leading cause of acquired resistance to imatinib, while the mechanisms underlying the persistence of minimal residual disease (MRD) are unknown. In this issue of Blood, Chu and colleagues report several patients with KD mutations at the time of complete cytogenetic response (CCR),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fusion Proteins, bcr-abl
Share to Imatinib Mesylate
Share to Benzamides

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Neoplasm, Residual

Share to Piperazines

Share to Pyrimidines

Source

Identifiers

PMID: 15747396
DOI: 10.1182/blood-2004-12-4764

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Can we afford to let sleeping dogs lie?PMID 15747396Read ↗

Why imatinib remains an exception of cancer researchSemantic proximity Read ↗

Another tyrosine kinase inhibitor-resistance mutation within the BCR-ABL kinase domain: chasing our tails?Semantic proximity Read ↗

Re-evaluating the role of BCR/ABL in chronic myelogenous leukemiaSemantic proximity Read ↗

BCR-ABL kinase is dead; long live the CML stem cellSemantic proximity Read ↗

Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder.Semantic proximity Read ↗

BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance.Semantic proximity Read ↗

Punish the parent not the progenySemantic proximity Read ↗

Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib.Semantic proximity Read ↗

Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatmentSemantic proximity Read ↗

Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy.Semantic proximity Read ↗

Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinibSemantic proximity Read ↗

Sequential acquisition of tyrosine kinase domain mutations in a case of chronic myeloid leukemia: A dormant clone war against TKISemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.